


Stereochemistry abstracts

Belén Altava*, Dalgi S. Barbosa, M. Isabel Burguete,
Jorge Escorihuela, Santiago V. Luis*

Tetrahedron: Asymmetry 20 (2009) 999





(S)-1-Benzyl-3-(1'hydroxy-1'diphenyl-4'-methyl-2'-pentanyl)imidazolium hexafluoroantimonide

$[\alpha]_D^{20} = +99.8$ (c 0.009, CH₃OH)
Source of chirality: L-isoleucine
Absolute configuration: (S)

Belén Altava*, Dalgi S. Barbosa, M. Isabel Burguete,
Jorge Escorihuela, Santiago V. Luis*

Tetrahedron: Asymmetry 20 (2009) 999





(S)-1-Benzyl-3-(1'hydroxy-1'diphenyl-3'phenyl-2'-propanyl)imidazolium hexafluoroantimonide

$[\alpha]_D^{20} = +35$ (c 0.010, CH₃OH)
Source of chirality: L-phenylalanine
Absolute configuration: (S)

Belén Altava*, Dalgi S. Barbosa, M. Isabel Burguete,
Jorge Escorihuela, Santiago V. Luis*

Tetrahedron: Asymmetry 20 (2009) 999




(S)-1-Benzyl-3-(1'-hydroxy-1'-diphenyl-2'-propanyl)imidazolium triflamide

$[\alpha]_D^{20} = +41.4$ (c 0.004, CH₃OH)
Source of chirality: L-phenylalanine
Absolute configuration: (S)


Belén Altava*, Dalgi S. Barbosa, M. Isabel Burguete,
Jorge Escorihuela, Santiago V. Luis*

Tetrahedron: Asymmetry 20 (2009) 999




(S)-1-Benzyl-3-(1'-hydroxy-1'-diphenyl-3'-methyl-2'-butanyl)imidazolium triflamide

$[\alpha]_D^{20} = +46.9$ (c 0.011, CH₃OH)
Source of chirality: L-valine
Absolute configuration: (S)




(S)-1-(1'naphthyl)-methyl-3-(1'-hydroxy-1'diphenyl-3'-phenyl-2'-propanyl)imidazolium triflamide

[α]_D²⁰ = +27.4 (c 0.005, CH₃OH)
Source of chirality: L-phenylalanine
Absolute configuration: (S)





(S)-1-(1'naphthyl)-methyl-3-(1'-hydroxy-1'diphenyl-3'-methyl-2'-butanyl)imidazolium triflamide

[α]_D²⁰ = +74.7 (c 0.011, CH₃OH)
Source of chirality: L-valine
Absolute configuration: (S)




2,2'-Dibromo-6,6'-diformylbiphenyl

Ee = 50%
[α]_D²⁰ = -29.9 (c 0.985, CHCl₃)
Source of chirality: asymmetric synthesis



(1R)-[(R)-2'-Ethoxy-1,1'-binaphth-2-yl] 2,2-dichlorocyclopropanecarboxylate

[α]_D²³ = +34.1 (c 1.80, CHCl₃)
Source of chirality: (R)-1,1'-binaphthol monoethyl ether
Absolute configuration: (1R)-[(R)]




(1S)-[(R)-2'-Ethoxy-1,1'-binaphth-2-yl] 2,2-dichlorocyclopropanecarboxylate

$[\alpha]_D^{23} = -38.6 \text{ (c 0.90, CHCl}_3\text{)}$

Source of chirality: (R)-1,1'-binaphthol monoethyl ether

Absolute configuration: (1S)-[(R)]




(1R)-[(R)-2'-Methoxy-1,1'-binaphth-2-yl] 2,2-dichlorocyclopropanecarboxylate

$[\alpha]_D^{23} = +36.9 \text{ (c 1.35, CHCl}_3\text{)}$

Source of chirality: (R)-1,1'-binaphthol monomethyl ether

Absolute configuration: (1R)-[(R)]





(1S)-[(R)-2'-Methoxy-1,1'-binaphth-2-yl] 2,2-dichlorocyclopropanecarboxylate

$[\alpha]_D^{24} = -39.7 \text{ (c 4.2, CHCl}_3\text{)}$

Source of chirality: (R)-1,1'-binaphthol monomethyl ether

Absolute configuration: (1S)-[(R)]




(1R)-[(R)-2'-Ethoxy-1,1'-binaphth-2-yl] 2,2-dimethylcyclopropanecarboxylate

$[\alpha]_D^{25} = +7.4 \text{ (c 1.00, CHCl}_3\text{)}$

Source of chirality: (R)-1,1'-binaphthol monoethyl ether

Absolute configuration: (1R)-[(R)]


 $C_{32}H_{32}O_3$

(1R,3R)-[(R)-2'-Ethoxy-1,1'-binaphth-2-yl]3-(2',2'-dimethylethenyl)-2,2-dimethylcyclopropanecarboxylate


 $[\alpha]_D^{24} = +88.5$ (*c* 1.00, CHCl₃)

Source of chirality: (R)-1,1'-binaphthol monoethyl ether

Absolute configuration: (1R,3R)-[(R)]

 $C_{32}H_{32}O_3$

(1S,3S)-[(R)-2'-Ethoxy-1,1'-binaphth-2-yl]3-(2',2'-dimethylethenyl)-2,2-dimethylcyclopropanecarboxylate


 $C_{30}H_{26}Cl_2O_3$

(1R,3S)-[(R)-2'-Ethoxy-1,1'-binaphth-2-yl]3-(2',2'-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate

 $[\alpha]_D^{29} = +77.4$ (*c* 1.00, CHCl₃)

Source of chirality: (R)-1,1'-binaphthol monoethyl ether

Absolute configuration: (1R,3S)-[(R)]


 $C_{30}H_{26}Cl_2O_3$

(1S,3R)-[(R)-2'-Ethoxy-1,1'-binaphth-2-yl]3-(2',2'-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate

 $[\alpha]_D^{25} = -40.2$ (*c* 4.45, CHCl₃)


Source of chirality: (R)-1,1'-binaphthol

Absolute configuration: (1S,3R)-[(R)]




$C_8H_{10}Cl_2O_2$
(1*R*,3*S*)-2,2-Dimethyl-3-(2',2'-dichloroethenyl)cyclopropanecarboxylic acid

Ee = 99%
 $[\alpha]_D^{23} = +25.1$ (*c* 1.10, CHCl₃)
 Source of chirality: asymmetric synthesis
 Absolute configuration: (1*R*,3*S*)




$C_{10}H_{16}O_2$
(1*R*,3*S*)-2,2-Dimethyl-3-(2',2'-dimethylethenyl)cyclopropanecarboxylic acid

Ee = 98%
 $[\alpha]_D^{23} = -38.6$ (*c* 0.90, CHCl₃)
 Source of chirality: asymmetric synthesis
 Absolute configuration: (1*R*,3*S*)




$C_8H_{10}Cl_2O_2$
(1*R*,3*R*)-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid

Ee = 99.8%
 $[\alpha]_{365}^{20} = +176.6$, $[\alpha]_{436}^{20} = +90.7$, $[\alpha]_{546}^{20} = +45.3$,
 $[\alpha]_{589}^{20} = +36.5$ (*c* 1.5, CH₂Cl₂)
 Source of chirality: stereoselective chromatography
 Absolute configuration: (1*R*,3*R*)




$C_8H_{10}Cl_2O_2$
(1*R*,3*S*)-3-(2,2-Dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid

Ee = 99.2%
 $[\alpha]_{365}^{20} = +154.7$, $[\alpha]_{436}^{20} = +90.6$, $[\alpha]_{546}^{20} = +49.2$,
 $[\alpha]_{589}^{20} = +40.3$ (*c* 1.5, CH₂Cl₂)
 Source of chirality: stereoselective chromatography
 Absolute configuration: (1*R*,3*S*)



Ee = 99.7%
 $[\alpha]_{365}^{20} = +19.7$, $[\alpha]_{436}^{20} = +8.5$, $[\alpha]_{546}^{20} = +3.7$, $[\alpha]_{589}^{20} = +2.6$
(*c* 1.5, CH_2Cl_2)
Source of chirality: synthesis from (1*R*,3*R*)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid
Absolute configuration: (1*R*,3*R*)


3-Phenoxybenzyl (1*R*,3*R*)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate



Ee = 99.3%
 $[\alpha]_{365}^{20} = -45.3$, $[\alpha]_{436}^{20} = -20.5$, $[\alpha]_{546}^{20} = -9.6$, $[\alpha]_{589}^{20} = -8.0$
(*c* 1.5, CH_2Cl_2)
Source of chirality: synthesis from (1*R*,3*S*)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylic acid
Absolute configuration: (1*R*,3*S*)


3-Phenoxybenzyl (1*R*,3*S*)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate

$[\alpha]_D^{20} = +4.1$ (*c* 9.83, CH_3OH)
Absolute configuration: (S)





L-(S)-Alanine methyl ester hydrochloride

$[\alpha]_D^{20} = +10.0$ (*c* 9.33, CH_3OH)
Absolute configuration: (S)




L-(S)-Alanylamide

$[\alpha]_D^{20} = +1.4$ (*c* 8.53, CHCl₃)
Absolute configuration: (S)





(S)-N,N,N',N'-Tetrakis[(ethoxy-carbonyl)methyl]-1,2-diaminopropane

$[\alpha]_D^{20} = +24.7$ (*c* 25.20, CH₃OH)
Absolute configuration: (S)





(S)-N,N,N',N'-Tetrakis[(hydroxy-carbonyl)methyl]-1,2-diamino-propane dihydrochloride

$[\alpha]_D = -96.6$ (*c* 0.54, CHCl₃)
Source of chirality: asymmetric hydrogenation
Absolute configuration: (R)




(R)-2-(1,2,3,4-Tetrahydroquinolin-2-yl)-1-phenylethanone

$[\alpha]_D = -87.3$ (*c* 1.06, CHCl₃)
Source of chirality: asymmetric hydrogenation
Absolute configuration: (R)




(R)-1-(1,2,3,4-Tetrahydroquinolin-2-yl)propan-2-one

$[\alpha]_D = -93.1$ (*c* 1.01, CHCl₃)
 Source of chirality: asymmetric hydrogenation
 Absolute configuration: (*R*)




C₁₄H₁₉NO
(R)-1-(1,2,3,4-Tetrahydroquinolin-2-yl)pentan-2-one

$[\alpha]_D = -80.0$ (*c* 1.12, CHCl₃)
 Source of chirality: asymmetric hydrogenation
 Absolute configuration: (*R*)




C₁₈H₁₆F₃NO
(R)-1-(4-(Trifluoromethyl)phenyl)-2-(1,2,3,4-tetrahydroquinolin-2-yl)ethanone

$[\alpha]_D = -70.3$ (*c* 1.32, CHCl₃)
 Source of chirality: asymmetric hydrogenation
 Absolute configuration: (*R*)



C₂₀H₂₃NO
(R)-2-(1,2,3,4-Tetrahydroquinolin-2-yl)-1-(4-isopropylphenyl)ethanone


$[\alpha]_D = -94.9$ (*c* 1.06, CHCl₃)
 Source of chirality: asymmetric hydrogenation
 Absolute configuration: (*R*)



C₁₈H₁₉NO
(R)-2-(1,2,3,4-Tetrahydroquinolin-2-yl)-1-o-tolylethanone

$[\alpha]_D = -145.7$ (*c* 1.12, CHCl₃)


Source of chirality: asymmetric hydrogenation

Absolute configuration: (*R*)C₂₁H₁₉NO

(R)-2-(1,2,3,4-Tetrahydroquinolin-2-yl)-1-(naphthalen-1-yl)ethanone

 $[\alpha]_D = -57.8$ (*c* 1.12, CHCl₃)


Source of chirality: asymmetric hydrogenation

Absolute configuration: (*R*)C₁₉H₂₁NO

(R)-1-(1,2,3,4-Tetrahydroquinolin-2-yl)-4-phenylbutan-2-one

 $[\alpha]_D = -48.9$ (*c* 0.50, CHCl₃)


Source of chirality: asymmetric hydrogenation

Absolute configuration: (*R*)C₁₇H₁₆FNO

(R)-2-(6-Fluoro-1,2,3,4-tetrahydroquinolin-2-yl)-1-phenylethanone



 $[\alpha]_D = -48.7$ (*c* 0.34, CHCl₃)

Source of chirality: asymmetric hydrogenation

Absolute configuration: (*R*)C₁₈H₁₉NO



(R)-2-(1,2,3,4-Tetrahydro-6-methylquinolin-2-yl)-1-phenylethanone

$[\alpha]_D = -77.2$ (*c* 0.74, CHCl₃)
 Source of chirality: asymmetric hydrogenation
 Absolute configuration: (*R*)





(*R*)-Methyl 2-(1,2,3,4-tetrahydroquinolin-2-yl)acetate

$[\alpha]_D = -69.8$ (*c* 1.00, CHCl₃)
 Source of chirality: asymmetric hydrogenation
 Absolute configuration: (*R*)





(*R*)-*N,N*-Diethyl-2-(1,2,3,4-tetrahydroquinolin-2-yl)acetamide

$[\alpha]_D = -53.9$ (*c* 1.21, CHCl₃)
 Source of chirality: asymmetric hydrogenation
 Absolute configuration: (*R*)



(*R*)-2-(1,2,3,4-Tetrahydroquinolin-2-yl)-1-(3,4-dimethoxyphenyl)ethanone

$[\alpha]_D = -59.9$ (*c* 1.00, CHCl₃)
 Source of chirality: asymmetric hydrogenation
 Absolute configuration: (*S*)




(*S*)-2-(3,4-Dimethoxyphenethyl)-1,2,3,4-tetrahydroquinoline

$[\alpha]_D = -27.2$ (*c* 0.87, CHCl₃)

Source of chirality: asymmetric hydrogenation

Absolute configuration: (S)




(S)-2-(3,4-Dimethoxyphenethyl)-1,2,3,4-tetrahydroquinoline

Ee = 78%

 $[\alpha]_D^{22.1} = -105.6$ (*c* 1.00, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (R)


(R)-Methyl 6-amino-5-cyano-4-phenyl-4*H*-pyran-2-carboxylate

Ee = 81%

 $[\alpha]_D^{22.1} = -68.1$ (*c* 1.00, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (R)


(R)-Methyl 6-amino-5-cyano-4-(4-fluorophenyl)-4*H*-pyran-2-carboxylate


Ee = 82%

 $[\alpha]_D^{22.1} = -132.4$ (*c* 1.00, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: (R)

(R)-Methyl 6-amino-4-(4-chlorophenyl)-5-cyano-4*H*-pyran-2-carboxylate




$C_{14}H_{11}BrN_2O_3$
(*R*)-Methyl 6-amino-4-(4-bromophenyl)-5-cyano-4*H*-pyran-2-carboxylate

Ee = 88%
 $[\alpha]_D^{22.1} = -50.7$ (*c* 1.00, CHCl₃);
 Source of chirality: asymmetric synthesis
 Absolute configuration: (*R*)




$C_{14}H_{10}Cl_2N_2O_3$
(*S*)-Methyl 6-amino-5-cyano-4-(2,4-dichlorophenyl)-4*H*-pyran-2-carboxylate

Ee = 88%
 $[\alpha]_D^{22.1} = -189.5$ (*c* 1.00, CHCl₃)
 Source of chirality: asymmetric synthesis
 Absolute configuration: (*S*)




$C_{14}H_{11}N_3O_5$
(*R*)-Methyl 6-amino-5-cyano-4-(4-nitrophenyl)-4*H*-pyran-2-carboxylate

Ee = 72%
 $[\alpha]_D^{22.1} = -10.3$ (*c* 1.00, CHCl₃)
 Source of chirality: asymmetric synthesis
 Absolute configuration: (*R*)



$C_{16}H_{16}N_2O_4$
(*R*)-Methyl 6-amino-5-cyano-4-(4-ethoxyphenyl)-4*H*-pyran-2-carboxylate

Ee = 85%
 $[\alpha]_D^{22.1} = -96.1$ (*c* 1.00, CHCl₃)
 Source of chirality: asymmetric synthesis
 Absolute configuration: (*R*)


(S)-Methyl 6-amino-4-(2-bromophenyl)-5-cyano-4*H*-pyran-2-carboxylate

Ee = 83%

 $[\alpha]_D^{22.1} = -173.5$ (c 1.00, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (S)


(R)-Methyl 6-amino-5-cyano-4-(2,5-dimethoxyphenyl)-4*H*-pyran-2-carboxylate

Ee = 80%

 $[\alpha]_D^{22.1} = -153.8$ (c 1.00, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (R)



(R)-Benzyl 6-amino-5-cyano-4-phenyl-4*H*-pyran-2-carboxylate

Ee = 80%

 $[\alpha]_D^{22.1} = -55.6$ (c 1.00, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (R)


(R)-4-Bromobenzyl 6-amino-5-cyano-4-phenyl-4*H*-pyran-2-carboxylate

Ee = 80%


 $[\alpha]_D^{22.1} = -50.1$ (c 1.00, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: (R)

(R)-Isopropyl 6-amino-5-cyano-4-phenyl-4*H*-pyran-2-carboxylate

Ee = 75%
 $[\alpha]_D^{22.1} = -63.0$ (*c* 1.00, CDCl₃)
 Source of chirality: asymmetric synthesis
 Absolute configuration: (R)


(R)-Allyl 6-amino-5-cyano-4-phenyl-4*H*-pyran-2-carboxylate

Ee = 77%
 $[\alpha]_D^{22.1} = -99.5$ (*c* 1.00, CDCl₃)
 Source of chirality: asymmetric synthesis
 Absolute configuration: (R)




(-)-(S)-1-Phenylethanol

Ee > 99% (HPLC, Chiralcel OB-H)
 $[\alpha]_D^{25} = -22.9$ (*c* 1.0, CH₂Cl₂)
 Source of chirality: enzymatic reduction
 Absolute configuration: (S)



(-)-(S)-1-(2-Methoxyphenyl)ethanol

Ee > 99% (HPLC, Chiralcel OB-H)
 $[\alpha]_D^{25} = -17.1$ (*c* 0.75, CHCl₃)
 Source of chirality: enzymatic reduction
 Absolute configuration: (S)



C₉H₁₂O₂


(-)-(S)-1-(3-Methoxyphenyl)ethanol

Ee 97% (HPLC, Chiralcel OB-H)

[α]_D²⁵ = -29.8 (c 0.85, MeOH)

Source of chirality: enzymatic reduction

Absolute configuration: (S)



C₉H₁₂O₂


(-)-(S)-1-(4-Methoxyphenyl)ethanol

Ee 99% (HPLC, Chiralcel OB-H)

[α]_D²⁵ = -29.1 (c 1.5, CHCl₃)

Source of chirality: enzymatic reduction

Absolute configuration: (S)



C₈H₉NO₃


(+)-(S)-1-(2-Nitrophenyl)ethanol

Ee 98% (HPLC, Chiralpak AS)

[α]_D²⁵ = +18.5 (c 0.23, MeOH)

Source of chirality: enzymatic reduction

Absolute configuration: (S)



C₈H₉NO₃


(-)-(S)-1-(3-Nitrophenyl)ethanol

Ee 98% (HPLC, Chiralcel OB-H)

[α]_D²⁵ = -20.5 (c 1.0, CHCl₃)


Source of chirality: enzymatic reduction

Absolute configuration: (S)




C₈H₉NO₃
(-)-(S)-1-(4-Nitrophenyl)ethanol

Ee > 99% (HPLC, Chiralpak AS)
 $[\alpha]_D^{25} = -20.5$ (c 1.2, CHCl₃)
Source of chirality: enzymatic reduction
Absolute configuration: (S)




C₉H₁₂O
(-)-(S)-1-(2-Methylphenyl)ethanol

Ee > 99% (HPLC, Chiralcel OB-H)
 $[\alpha]_D^{25} = -25.1$ (c 0.54, CHCl₃)
Source of chirality: enzymatic reduction
Absolute configuration: (S)




C₈H₉ClO
(-)-(R)-2-Chloro-1-phenylethanol

Ee 78% (HPLC, Chiralcel OB-H)
 $[\alpha]_D^{25} = -42.5$ (c 0.87, CH₂Cl₂)
Source of chirality: enzymatic reduction
Absolute configuration: (R)




C₈H₇Cl₃O
(-)-(R)-2-Chloro-1-(3,4-dichlorophenyl)ethanol

Ee 91% (HPLC, Chiralpak IA)
 $[\alpha]_D^{25} = -32.7$ (c 1.0, CHCl₃)
Source of chirality: enzymatic reduction
Absolute configuration: (R)




Ee = 95%
 $[\alpha]_D = +2.0$ (*c* 1.0, CHCl₃)
 Absolute configuration: (S)

C₈H₁₄O
 (S)-4-methyl-1-hepten-3-one




Ee = 95%
 $[\alpha]_D = +15.8$ (*c* 1.0, CHCl₃)
 Absolute configuration: (S)

C₆H₁₂O₂
 (S)-2-methylpentanoic acid




$[\alpha]_D = +18.3$ (*c* 1.0, CHCl₃)
 Absolute configuration: (2S)

C₈H₁₇NO₂
 (2S)-N-Methoxy-N,2-dimethylpentanamide



Ee = 100%
 $[\alpha]_D^{25} = -12.5$ (*c* 0.6, CH₂Cl₂)
 Source of chirality: asymmetric synthesis
 Absolute configuration: 3,5-O-(*S,E*)-, α -D-xylofuranose

C₁₇H₁₉NO₇
 1,2-O-isopropylidene-3,5-O-[(*S,E*)-3-(2-nitrophenyl)-2-propenylidene]- α -D-xylofuranose




$C_{18}H_{22}O_6$
1,2-O-isopropylidene-3,5-O-[(*S,E*)-3-(2-methoxyphenyl)-2-propenylidene]- α -D-xylofuranose

Ee = 100%

 $[\alpha]_D^{25} = +5.4$ (*c* 1.0, CH_2Cl_2)

Source of chirality: asymmetric synthesis


Absolute configuration: 3,5-O-(*S,E*)-, α -D-xylofuranose

$C_{18}H_{22}O_6$
1,2-O-isopropylidene-3,5-O-[(*S,E*)-3-(4-methoxyphenyl)-2-propenylidene]- α -D-xylofuranose

Ee = 100%

 $[\alpha]_D^{25} = +13.0$ (*c* 1.0, CH_2Cl_2)

Source of chirality: chiral pool


Absolute configuration: 3,5-O-(*S,E*)-, α -D-xylofuranose

$C_{19}H_{25}NO_5$
3,5-O-[(*S,E*)-3-(4-Dimethylaminophenyl)-2-propenylidene]-1,2-O-isopropylidene- α -D-xylofuranose

Ee = 100%

 $[\alpha]_D^{25} = +19.3$ (*c* 1.0, CH_2Cl_2)

Source of chirality: chiral pool

Absolute configuration: 3,5-O-(*S,E*)-, α -D-xylofuranose


$C_{12}H_{18}O_5$
3,5-O-[(*S,E*)-2-Butenylidene]-1,2-O-isopropylidene- α -D-xylofuranose

Ee = 100%



 $[\alpha]_D^{25} = -6.2$ (*c* 1.1, CH_2Cl_2)

Source of chirality: chiral pool



Absolute configuration: 3,5-O-(*S,E*)-, α -D-xylofuranose





Ee = 100%
 $[\alpha]_D^{25} = -3.6$ (c 1.3, CH₂Cl₂)
 Source of chirality: chiral pool
 Absolute configuration: 3,5-O-(S,E)-, α -D-xylofuranose

3,5-O-[(S,E)-2-Decenylidene]-1,2-O-isopropylidene- α -D-xylofuranose

Ee = 100%
 $[\alpha]_D^{25} = -53.7$ (c 1.0, CH₂Cl₂)
 Source of chirality: chiral pool
 Absolute configuration: 3,5-O-(S)-, α -D-xylofuranose


3,5-O-[(S)-3,3-Diphenyl-2-propenylidene]-1,2-O-isopropylidene- α -D-xylofuranose

Ee = 100%
 $[\alpha]_D^{25} = +15.0$ (c 1.0, CH₂Cl₂)
 Source of chirality: chiral pool
 Absolute configuration: 3,5-O-(S,E)-, α -D-xylofuranose


3,5-O-[(S,E)-2-Hexyl-3-phenyl-2-propenylidene]-1,2-O-isopropylidene- α -D-xylofuranose

Ee = 100%
 $[\alpha]_D^{25} = -52.9$ (c 1.2, CH₂Cl₂)
 Source of chirality: chiral pool
 Absolute configuration: 3,5-O-(S,Z)-, α -D-xylofuranose


3,5-O-[(S,Z)-2-Hexyl-3-phenyl-2-propenylidene]-1,2-O-isopropylidene- α -D-xylofuranose

 $Ee = 100\%$ $[\alpha]_D^{25} = -2.8$ (c 1.0, CH_2Cl_2)


Source of chirality: chiral pool

Absolute configuration: 3,5-O-(S)-, α -D-xylofuranose $C_{15}\text{H}_{22}\text{O}_5$ 3,5-O-[(S)-(1-Cyclohexenyl)methylidene]-1,2-O-isopropylidene- α -D-xylofuranose $De = 82\%$ $[\alpha]_D^{25} = -61.7$ (c 1.0, CH_2Cl_2)

Source of chirality: asymmetric synthesis


Absolute configuration: 3,5-O-(1S,2R,3R)-, α -D-xylofuranose $C_{18}\text{H}_{22}\text{O}_5$ 1,2-O-Isopropylidene-3,5-O-[(1S,2R,3R)-(2-phenylcyclopropyl)methylidene]- α -D-xylofuranose $De = 78\%$ $[\alpha]_D^{25} = -42.8$ (c 1.0, CH_2Cl_2)

Source of chirality: asymmetric synthesis

Absolute configuration: 3,5-O-(1S,2R,3R)-, α -D-xylofuranose $C_{18}\text{H}_{21}\text{NO}_7$ 1,2-O-Isopropylidene-3,5-O-[(1S,2R,3R)-2-[(2-nitrophenyl)cyclopropyl)methylidene]- α -D-xylofuranose $De = 77\%$ $[\alpha]_D^{25} = -60.6$ (c 1.0, CH_2Cl_2)

Source of chirality: asymmetric synthesis


Absolute configuration: 3,5-O-(1S,2R,3R)-, α -D-xylofuranose $C_{19}\text{H}_{24}\text{O}_6$ 1,2-O-Isopropylidene-3,5-O-[(1S,2R,3R)-2-[(2-methoxyphenyl)cyclopropyl)methylidene]- α -D-xylofuranose

 $C_{19}H_{24}O_6$ 1,2-O-isopropylidene-3,5-O-[(1S,2R,3R)-2-[(4-methoxyphenyl)cyclopropyl]methylidene]- α -D-xylofuranose

De = 46%

 $[\alpha]_D^{25} = -36.9$ (*c* 1.0, CH_2Cl_2)


Source of chirality: asymmetric synthesis

Absolute configuration: 3,5-O-(1S,2R,3R)-, α -D-xylofuranose $C_{13}H_{20}O_5$ 1,2-O-isopropylidene-3,5-O-[(1S,2R,3R)-(2-methylcyclopropyl)methylidene]- α -D-xylofuranose

De = 65%

 $[\alpha]_D^{25} = -21.2$ (*c* 1.0, CH_2Cl_2)


Source of chirality: asymmetric synthesis

Absolute configuration: 3,5-O-(1S,2R,3R)-, α -D-xylofuranose $C_{19}H_{32}O_5$ 3,5-O-[(1S,2R,3R)-(2-heptylcyclopropyl)methylidene]-1,2-O-isopropylidene- α -D-xylofuranose

De = 100%

 $[\alpha]_D^{25} = -26.7$ (*c* 1.0, CH_2Cl_2)

Source of chirality: asymmetric synthesis


Absolute configuration: 3,5-O-(1S,2R,3R)-, α -D-xylofuranose $C_{24}H_{26}O_5$ 3,5-O-[(1S,2R)-2,2-diphenylcyclopropyl)methylidene]-1,2-O-isopropylidene- α -D-xylofuranose

De = 100%

 $[\alpha]_D^{25} = +77.0$ (*c* 1.1, CH_2Cl_2)

Source of chirality: asymmetric synthesis


Absolute configuration: 3,5-O-(1S,2R)-, α -D-xylofuranose

 $C_{19}H_{24}O_5$ 1,2-O-isopropylidene-3,5-O-[(1S,2R,3S)-(1-methyl-2-phenylcyclopropyl)methylidene]- α -D-xylofuranose

De = 76%

 $[\alpha]_D^{25} = -17.8$ (c 0.9, CH_2Cl_2)


Source of chirality: asymmetric synthesis

Absolute configuration: 3,5-O-(1S,2R,3S)-, α -D-xylofuranose $C_{24}H_{34}O_5$ 3,5-O-[(1S,2R,3S)-(1-hexyl-2-phenylcyclopropyl)methylidene]-1,2-O-isopropylidene- α -D-xylofuranose

De = 66%

 $[\alpha]_D^{25} = -16.9$ (c 0.9, CH_2Cl_2)


Source of chirality: asymmetric synthesis

Absolute configuration: 3,5-O-(1S,2R,3S)-, α -D-xylofuranose $C_{16}H_{24}O_5$ 1,2-O-isopropylidene-3,5-O-[(1S,2R,3R)-(1,2-methylenecyclohexyl)methylidene]- α -D-xylofuranose

De = 67%

 $[\alpha]_D^{25} = -10.0$ (c 1.0, CH_2Cl_2)

Source of chirality: asymmetric synthesis

Absolute configuration: 3,5-O-(1S,2R,3R)-, α -D-xylofuranose $C_{11}H_{22}O$


(1R,2R)-trans-1-heptyl-2-hydroxymethylcyclopropane

Ee = 100%



 $[\alpha]_D^{25} = -17.6$ (c 0.5, CH_2Cl_2)

Source of chirality: asymmetric synthesis

Absolute configuration: (1R,2R)-trans-


(S)-1-(2-Hydroxypropyl)-4,5-dimethyl-1*H*-imidazole

Ee = 100%
 $[\alpha]_D^{20} = +69.2$ (*c* 0.2, CH_2Cl_2)
 Source of chirality: chiral substrate
 Absolute configuration: (S)

Methyl (S)-2-(4,5-dimethyl-1*H*-imidazol-1-yl)propanoate


(S)-1-Butoxy-4,5-dimethyl-3-(2-hydroxypropyl)imidazolium bromide

Ee = 100%
 $[\alpha]_D^{20} = +13.7$ (*c* 0.2, CH_2Cl_2)
 Source of chirality: chiral substrate
 Absolute configuration: (S)




(S)-1-Butoxy-4,5-dimethyl-3-(1-[methoxycarbonyl]ethyl)imidazolium bromide

Ee = 100%
 $[\alpha]_D^{20} = +14.2$ (*c* 0.2, CH_2Cl_2)
 Source of chirality: chiral substrate
 Absolute configuration: (S)




Ee = 100%
 $[\alpha]_D^{20} = +11.1$ (c 0.2, CH₂Cl₂)
 Source of chirality: chiral substrate
 Absolute configuration: (S)

(S)-4,5-Dimethyl-1-hexyloxy-3-(1-[methoxycarbonyl]ethyl)imidazolium bromide




Ee = 100%
 $[\alpha]_D^{20} = +21.8$ (c 0.2, CH₂Cl₂)
 Source of chirality: chiral substrate
 Absolute configuration: (S)

(S)-1-Butoxy-4,5-dimethyl-3-(2-hydroxypropyl)imidazolium tetrafluoroborate




Ee = 100%
 $[\alpha]_D^{20} = +14.7$ (c 0.2, CH₂Cl₂)
 Source of chirality: chiral substrate
 Absolute configuration: (S)

(S)-1-Butoxy-4,5-dimethyl-3-(1-[methoxycarbonyl]ethyl)imidazolium tetrafluoroborate




Ee = 100%
 $[\alpha]_D^{20} = +9.5$ (c 0.2, CH₂Cl₂)
 Source of chirality: chiral substrate
 Absolute configuration: (S)

(S)-4,5-Dimethyl-1-hexyloxy-3-(1-[methoxycarbonyl]ethyl)imidazolium tetrafluoroborate




(S)-3-Butyl-4,5-dimethyl-1-(2-hydroxypropyl)imidazolium bromide

Ee = 100%
 $[\alpha]_D^{20} = +13.8$ (*c* 0.2, CH₂Cl₂)
 Source of chirality: chiral substrate
 Absolute configuration: (S)




(S)-1-Butyl-3-(1-[methoxycarbonyl]ethyl)-4,5-dimethylimidazolium bromide

Ee = 100%
 $[\alpha]_D^{20} = +11.2$ (*c* 0.2, CH₂Cl₂)
 Source of chirality: chiral substrate
 Absolute configuration: (S)





(S)-1-Butyl-4,5-dimethyl-3-(2-hydroxypropyl)imidazolium tetrafluoroborate

Ee = 100%
 $[\alpha]_D^{20} = +21.2$ (*c* 0.2, CH₂Cl₂)
 Source of chirality: chiral substrate
 Absolute configuration: (S)



(S)-1-Butyl-4,5-dimethyl-3-(1-[methoxycarbonyl]ethyl)imidazolium tetrafluoroborate

Ee = 100%
 $[\alpha]_D^{20} = +10.3$ (*c* 0.2, CH₂Cl₂)
 Source of chirality: chiral substrate
 Absolute configuration: (S)




(S_P,S_P)-(-)-(E)-1,2-Bis(methylphenylphosphinoyl)ethene

Ee 98%

$[\alpha]_D^{20} = -255.0$ (*c* 1, CH₂Cl₂)

Source of chirality: resolution of precursor

Absolute configuration: (S_P,S_P)




($S_P,S_P,5R,6R$)-*endo*-5-*exo*-6-Di(methylphenylphosphanoyl)bicyclo[2.2.1]hept-2-ene

Ee 98%, de 96%

$[\alpha]_D^{20} = -83.5$ (*c* 0.69, CHCl₃)

Source of chirality: resolution of precursor, stereoselective reaction

Absolute configuration: ($S_P,S_P,5R,6R$)




($S_P,S_P,5S,6S$)-*endo*-5-*exo*-6-Di(methylphenylphosphanoyl)bicyclo[2.2.1]hept-2-ene

Ee 98%, de 90%

$[\alpha]_D^{20} = +15.4$ (*c* 0.72, CHCl₃)

Source of chirality: resolution of precursor, stereoselective reaction

Absolute configuration: ($S_P,S_P,5S,6S$)




(*S*)-tert-Butyl-2-((*R*)-2'-(diphenylphosphino)-1,1'-binaphthyl-2-ylcarbamoyl)pyrrolidine-2-carboxylate

Ee = 100%

$[\alpha]_D^{20} = -22.4$ (*c* 0.91, CHCl₃)

Source of chirality: (*R*)-BINOL, L-proline


Absolute configuration: (1*R*,2*S*)

 $C_{37}H_{31}N_2OP$ (2S)-*N*-((R)-1-(2-(Diphenylphosphino)naphthalen-1-yl)naphthalen-2-yl)pyrrolidine-2-carboxamide

Ee = 100%

 $[\alpha]_D^{20} = -11.4$ (*c* 2.18, CHCl₃)

Source of chirality: (R)-BINOL, L-proline

Absolute configuration: (1*R*,2*S*) $C_{37}H_{31}N_2OP$ (2*R*)-*N*-((R)-1-(2-(Diphenylphosphino)naphthalen-1-yl)naphthalen-2-yl)pyrrolidine-2-carboxamide

Ee = 100%

 $[\alpha]_D^{20} = +20.1$ (*c* 0.53, CHCl₃)

Source of chirality: (R)-BINOL, D-proline

Absolute configuration: (1*R*,2*R*)